| __timestamp | Bristol-Myers Squibb Company | Sanofi |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 8565000000 |
| Thursday, January 1, 2015 | 5001000000 | 9496000000 |
| Friday, January 1, 2016 | 5002000000 | 9592000000 |
| Sunday, January 1, 2017 | 4849000000 | 10164000000 |
| Monday, January 1, 2018 | 4551000000 | 9934000000 |
| Tuesday, January 1, 2019 | 4871000000 | 9883000000 |
| Wednesday, January 1, 2020 | 7661000000 | 9390000000 |
| Friday, January 1, 2021 | 7690000000 | 9555000000 |
| Saturday, January 1, 2022 | 7814000000 | 10539000000 |
| Sunday, January 1, 2023 | 7772000000 | 10765000000 |
| Monday, January 1, 2024 | 8414000000 | 9183000000 |
Igniting the spark of knowledge
In the competitive pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Sanofi and Bristol-Myers Squibb Company have showcased contrasting strategies in this domain. From 2014 to 2023, Sanofi consistently reported higher SG&A expenses, peaking at approximately $10.8 billion in 2023. In contrast, Bristol-Myers Squibb's expenses fluctuated, reaching a high of around $7.8 billion in 2022.
Despite Sanofi's higher absolute costs, their expenses grew by about 26% over the period, while Bristol-Myers Squibb saw a 36% increase. This suggests that Sanofi may have a more stable cost management strategy. As these companies continue to innovate and expand, their ability to optimize SG&A costs will remain a key factor in maintaining competitive advantage.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Sanofi or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Sanofi or Teva Pharmaceutical Industries Limited
Sanofi or Jazz Pharmaceuticals plc: Who Manages SG&A Costs Better?
Sanofi and Grifols, S.A.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Wave Life Sciences Ltd.